Mark Sheptoff Financial Planning LLC Cuts Position in DexCom, Inc. (NASDAQ:DXCM)

Mark Sheptoff Financial Planning LLC reduced its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 38.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,990 shares of the medical device company’s stock after selling 1,870 shares during the quarter. Mark Sheptoff Financial Planning LLC’s holdings in DexCom were worth $233,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Geode Capital Management LLC increased its holdings in DexCom by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock valued at $664,056,000 after purchasing an additional 214,136 shares in the last quarter. Jennison Associates LLC grew its stake in shares of DexCom by 10.3% in the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after buying an additional 710,858 shares in the last quarter. Groupama Asset Managment raised its holdings in shares of DexCom by 1.1% during the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock valued at $1,912,000 after buying an additional 31,358 shares during the period. Charles Schwab Investment Management Inc. lifted its position in DexCom by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company’s stock worth $219,716,000 after acquiring an additional 91,051 shares in the last quarter. Finally, Congress Asset Management Co. boosted its holdings in DexCom by 5,456.9% in the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock worth $105,529,000 after acquiring an additional 1,332,522 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $73.55 on Wednesday. The company has a market cap of $28.74 billion, a PE ratio of 51.43, a P/E/G ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The firm has a 50-day simple moving average of $83.13 and a 200 day simple moving average of $77.11. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, sell-side analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Cfra Research upgraded shares of DexCom to a “hold” rating in a research note on Friday, March 21st. Morgan Stanley lifted their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and upped their price objective for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Finally, Canaccord Genuity Group increased their price target on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $99.82.

Insider Buying and Selling at DexCom

In related news, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the sale, the chief executive officer now directly owns 372,029 shares in the company, valued at $26,183,401.02. This trade represents a 8.03 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 14,076 shares of the business’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the transaction, the chief operating officer now directly owns 313,497 shares of the company’s stock, valued at $22,063,918.86. The trade was a 4.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 105,009 shares of company stock worth $8,044,178. 0.30% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.